Wells Fargo
MBRX icon

Wells Fargo’s Moleculin Biotech MBRX Stock Holding History

Wells Fargo’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558 Buy
+200
New +$511 ﹤0.01% 6510
2024
Q2 		– Sell
-1
Closed -$112 – 7234
2024
Q1 		$112 Hold
1
– – ﹤0.01% 6626
2023
Q4 		$197 Sell
1
-1
-50% -$208 ﹤0.01% 6615
2023
Q3 		$307 Buy
2
+1
+100% +$207 ﹤0.01% 6472
2023
Q2 		$124 Hold
1
– – ﹤0.01% 6826
2023
Q1 		$190 Hold
1
– – ﹤0.01% 6788
2022
Q4 		$552 Hold
1
– – ﹤0.01% 6361
2022
Q3 		$0 Hold
1
– – ﹤0.01% 7080
2022
Q2 		$0 Sell
1
-10
-91% -$5.82K ﹤0.01% 7213
2022
Q1 		$7K Hold
11
– – ﹤0.01% 6386
2021
Q4 		$7K Buy
+11
New +$9.76K ﹤0.01% 6638
2021
Q3 		– Hold
0
– – – 6740
2021
Q2 		– Hold
0
– – – 6691
2021
Q1 		– Hold
0
– – – 6740
2020
Q4 		– Sell
-37
Closed -$65.7K – 6795
2020
Q3 		$67K Buy
37
+2
+6% +$4.25K ﹤0.01% 5404
2020
Q2 		$76K Buy
+35
New +$83K ﹤0.01% 5349
2020
Q1 		– Sell
-1
Closed -$1.7K – 6558
2019
Q4 		$3K Hold
1
– – ﹤0.01% 6123
2019
Q3 		$3K Hold
1
– – ﹤0.01% 6145
2019
Q2 		$3K Buy
+1
New +$2.72K ﹤0.01% 6117
2018
Q2 		– Sell
-2
Closed -$9K – 6466
2018
Q1 		$9K Buy
+2
New +$8.65K ﹤0.01% 5964

Other funds holding MBRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wells Fargo's MBRX Position: Q2 2026 in Review

Wells Fargo opened a new position in Moleculin Biotech (MBRX) in Q2 2026: 200 shares worth $558. The stake represents ﹤0.01% of the portfolio and ranks #6510 among its holdings. This is a return to the name: Wells Fargo previously reported a position in MBRX as recently as Q1 2024.

Wells Fargo first reported a position in MBRX in Q1 2018 and has held it in 17 quarters since. The position peaked at $76K in Q2 2020. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Wells Fargo held 200 shares of Moleculin Biotech worth $558 as of Q2 2026.
  • Moleculin Biotech was a new Wells Fargo position in Q2 2026.
  • Moleculin Biotech made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #6510 holding.
  • Wells Fargo first reported a position in Moleculin Biotech in Q1 2018 and has held it in 17 quarters since.
  • Wells Fargo's Moleculin Biotech position peaked at $76K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.